	US 11,834,679 B2
	Method for producing cardiomyocytes
Ping Dai, Kyoto (JP); Yukimasa Takeda, Kyoto (JP); Yoshinori Harada, Kyoto (JP); Junichi Matsumoto, Kyoto (JP); and Ayumi Kusaka, Kyoto (JP)
Assigned to Kataoka Corporation, Kyoto (JP); and Kyoto Prefectural Public University Corporation, Kyoto (JP)
Appl. No. 16/960,441
Filed by KATAOKA CORPORATION, Kyoto (JP); and Kyoto Prefectural Public University Corporation, Kyoto (JP)
PCT Filed Jan. 24, 2019, PCT No. PCT/JP2019/002193 § 371(c)(1), (2) Date Jul. 7, 2020, PCT Pub. No. WO2019/151097, PCT Pub. Date Aug. 8, 2019.
Claims priority of application No. 2018-013301 (JP), filed on Jan. 30, 2018.
Prior Publication US 2020/0354680 A1, Nov. 12, 2020
Int. Cl. C12N 5/077 (2010.01)

CPC C12N 5/0657 (2013.01) [C12N 2506/1307 (2013.01)]

8 Claims

1. A process for producing a myocardial-like cell, comprising a step of culturing a fibroblast as a starting material in the presence of a MEK inhibitor, a cAMP inducer, a PDE4 inhibitor, and a GR agonist, or in the presence of a MEK inhibitor, a cAMP inducer, a PDE4 inhibitor, a TGF β inhibitor, and a GR agonist under a basal medium supplemented by at least one member selected from the group consisting of serum, a protein, an amino acid, a sugar, a vitamin, a fatty acid, and an antibiotic, and culture conditions for directly inducing differentiation of a fibroblast into a myocardial-like cell, wherein a myocardial-like cell is produced.